{"entity":{"id":"idea-lung-brain-metastasis-prevention-as-a-primary-endpoint","kind":"idea","name":"Measure brain metastasis prevention as a primary endpoint, not as a secondary one","aka":[],"tldr":"Lung cancer spreads to the brain more than any other common cancer, and the newest drugs seem to stop it happening. Almost no trial is designed to prove that, so the claim stays a footnote.","summary":"Prophylactic cranial irradiation is the proof of principle: Aupérin's overview of 987 patients showed that treating a brain with no visible disease in it extends life in small-cell lung cancer. In non-small-cell disease, alectinib, lorlatinib and osimertinib all appear to prevent as well as treat central nervous system disease, and CROWN's intracranial response figures and ALINA's central nervous system disease-free survival are the strongest evidence for it. But these are secondary endpoints, measured with inconsistent imaging schedules, in trials powered for something else.\n\nThe idea is to design for it: brain-metastasis-free survival as a primary endpoint, with protocol-mandated MRI at fixed intervals, in the populations where the risk is highest. Prevention of brain metastases is a distinct clinical good, and the current evidence base does not let anyone say by how much any drug delivers it.","asOf":"2026-09-25","links":[],"tags":["lung-evidence"],"related":["idea-bio2-brain-met-prevention-trials","idea-tr1-brain-mets-default-included","idea-fund-brain-metastases-programme","lung-cancer-evidence-roadmap"],"cancers":["lung-cancer","nsclc","sclc","alk-positive-nsclc","egfr-mutant-nsclc"],"sections":["targeted-therapy","radiation"],"technologies":["stereotactic-radiosurgery","radiotherapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["brain-metastases","prophylactic-cranial-irradiation"],"trials":[],"people":[],"bottlenecks":["b-brain-delivery","b-trial-design","b-toxicity-qol","b-metastasis-biology"],"keyPapers":["paper-auperin-prophylactic-cranial-irradiation-sclc-nejm-1999","paper-shaw-crown-lorlatinib-crizotinib-nejm-2020","paper-peters-alex-alectinib-crizotinib-nejm-2017","paper-wu-alina-adjuvant-alectinib-nejm-2024"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"In driver-positive non-small-cell lung cancer, a central-nervous-system-penetrant inhibitor given from diagnosis reduces the cumulative incidence of brain metastases compared with a non-penetrant one, by an amount large enough to justify choosing between drugs on that basis and to change quality of life and cognitive outcomes.","rationale":"Brain metastases are the dominant failure pattern in ALK-positive and EGFR-mutant disease treated with first-generation inhibitors, and the main reason patients receive whole-brain radiotherapy with its cognitive cost. The prophylactic cranial irradiation precedent shows pre-emptive treatment of the sanctuary site can extend life. Drugs designed for brain penetration already exist, so this is a trial design problem rather than a drug discovery problem.","test":"Randomised trials in driver-positive disease with brain-metastasis-free survival as a primary endpoint and protocol-mandated MRI every three months, including patients with treated and asymptomatic central nervous system disease rather than excluding them, and with a cognitive and quality-of-life co-primary. Also a regulatory step: accepting brain-metastasis-free survival as a registrable endpoint.","maturity":"early-clinical","actor":"regulator","cost":"large","horizonYears":6},"route":"/ideas/idea-lung-brain-metastasis-prevention-as-a-primary-endpoint/","neighbours":{"idea":[{"id":"idea-tr1-brain-mets-default-included","kind":"idea","name":"Brain metastases included by default in every solid-tumour trial","route":"/ideas/idea-tr1-brain-mets-default-included/"},{"id":"idea-bio2-brain-met-prevention-trials","kind":"idea","name":"Prevention trials aimed only at brain metastasis","route":"/ideas/idea-bio2-brain-met-prevention-trials/"},{"id":"idea-fund-brain-metastases-programme","kind":"idea","name":"Treat brain metastases as a disease with its own trials programme","route":"/ideas/idea-fund-brain-metastases-programme/"}],"roadmap":[{"id":"lung-cancer-evidence-roadmap","kind":"roadmap","name":"Lung cancer roadmap: from Doll and Hill and the naming of tobacco, through the cytotoxic plateau, computed tomography screening, EGFR and ALK, immunotherapy by PD-L1, the perioperative trials and PACIFIC, to DLL3 in small-cell disease and a 2032 registry watch","route":"/roadmaps/lung-cancer-evidence-roadmap/"}],"cancer":[{"id":"alk-positive-nsclc","kind":"cancer","name":"ALK-positive non-small-cell lung cancer","route":"/cancers/alk-positive-nsclc/"},{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"section":[{"id":"radiation","kind":"section","name":"Radiation Therapy","route":"/fronts/radiation/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"term":[{"id":"brain-metastases","kind":"term","name":"Brain metastases (intracranial disease)","route":"/terms/brain-metastases/"},{"id":"radiotherapy","kind":"term","name":"Radiotherapy","route":"/terms/radiotherapy/"},{"id":"stereotactic-radiosurgery","kind":"term","name":"Stereotactic radiosurgery (SRS)","route":"/terms/stereotactic-radiosurgery/"}],"technology":[{"id":"prophylactic-cranial-irradiation","kind":"technology","name":"Prophylactic cranial irradiation vs MRI surveillance","route":"/technologies/prophylactic-cranial-irradiation/"}],"bottleneck":[{"id":"b-metastasis-biology","kind":"bottleneck","name":"Metastasis is understood least and studied last","route":"/bottlenecks/b-metastasis-biology/"},{"id":"b-brain-delivery","kind":"bottleneck","name":"The brain: barrier and sanctuary","route":"/bottlenecks/b-brain-delivery/"},{"id":"b-toxicity-qol","kind":"bottleneck","name":"Toxicity and quality of life are undervalued","route":"/bottlenecks/b-toxicity-qol/"},{"id":"b-trial-design","kind":"bottleneck","name":"Trial design, endpoints and cost","route":"/bottlenecks/b-trial-design/"}],"paper":[{"id":"paper-wu-alina-adjuvant-alectinib-nejm-2024","kind":"paper","name":"Alectinib in resected ALK-positive non-small-cell lung cancer","route":"/key-papers/paper-wu-alina-adjuvant-alectinib-nejm-2024/"},{"id":"paper-peters-alex-alectinib-crizotinib-nejm-2017","kind":"paper","name":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","route":"/key-papers/paper-peters-alex-alectinib-crizotinib-nejm-2017/"},{"id":"paper-shaw-crown-lorlatinib-crizotinib-nejm-2020","kind":"paper","name":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","route":"/key-papers/paper-shaw-crown-lorlatinib-crizotinib-nejm-2020/"},{"id":"paper-auperin-prophylactic-cranial-irradiation-sclc-nejm-1999","kind":"paper","name":"Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission","route":"/key-papers/paper-auperin-prophylactic-cranial-irradiation-sclc-nejm-1999/"}]}}